Skip to main content

Table 2 Changes in organ damage before and after the introduction of MPZ

From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis

  Pre-MPZ Post-MPZ
-12 M -11 M -9 M -6 M 0 M 1 M 3 M 6 M 12 M
General symptoms 0 0 1 (6.3%) 1 (6.3%) 1 (6.3%) 1 (6.3%) 0 1 (6.3%) 0
Cutaneous manifestations 1 (6.3%) 1 (6.3%) 1 (6.3%) 1 (6.3%) 2 (12.5%) 2 (12.5%) 0 1 (6.3%) 0
ENT manifestations 6 (37.5%) 6 (37.5%) 6 (37.5%) 6 (37.5%) 6 (37.5%) 6 (37.5%) 6 (37.5%) 4 (25.0%) 3 (18.8%)
Chest manifestations 6 (37.5%) 6 (37.5%) 8 (50.0%) 8 (50.0%) 11 (68.8%) 5 (31.3%) 2 (12.5%) 2 (12.5%) 2 (12.5%)
Nervous system manifestations 7 (45.8%) 7 (45.8%) 7 (45.8%) 8 (50.0%) 8 (50.0%) 8 (50.0%) 7 (43.8%) 7 (43.8%) 7 (43.8%)
  1. ENT ear, nose, throat